InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
On November 10, 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on anti-inflammatory treatments targeting the complement system, announced positive topline results from a Phase 2a basket study of INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).
Study Details and Efficacy
The study evaluated 29 of 31 HS patients and 30 of 31 CSU patients for efficacy, with a focus on safety and pharmacokinetics/pharmacodynamics. Efficacy outcomes were considered exploratory endpoints. InflaRx views the data as a strong foundation for continued development of INF904 in both indications.
The Phase 2a trial is ongoing, with completion aimed after a 4-week post-treatment observation period. Final results are expected to be presented at major scientific conferences.
Company Plans and Commentary
InflaRx plans to hold a Capital Markets Event soon to present the potential of INF904.
Riedemann, CEO and Founder of InflaRx, stated: “The success of our Phase 2a trial with INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) is a crucial milestone in demonstrating the compound’s strong safety profile and clinical activity as a potent anti-inflammatory agent. These data represent a pivotal moment for the company, underscoring the therapeutic promise of INF904 as a pipeline-in-a-product.”
Summary: INF904 shows promising safety and preliminary efficacy in Phase 2a trials for HS and CSU, supporting further development and upcoming detailed results presentations.
Would you like the summary to be more detailed or concise?